Companies: 10,795·Total market cap: $144.5T
Mithra Pharmaceuticals S.A.

Mithra Pharmaceuticals S.A.

MITPFOTCHealthcare
$23.90
+$17.15(+254.07%)
Market Cap$1.6B
P/E Ratio—
52W High$23.9
52W Low$6.75
Free Cash FlowFinancialsRevenue

Mithra Pharmaceuticals S.A. (MITPF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

MITPF · free cash flow · updated Jun 8, 2026

Core FCF metrics

Free cash flow was −$2.2M for FY2023 (fiscal year ending 2023-12-31), up 97.6% year-over-year The FCF margin was -5.4%.

FY2023 Free Cash Flow−$2.2M▲ +97.6% YoY
Trailing 12M (TTM)−$99.8Mtrailing 4 quarters sum
FCF Margin-5.4%−$2.2M ÷ revenue
3-Year CAGRN/AN/A — contains negative FCF
5-Year CAGRN/AN/A — contains negative FCF
FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0
Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

Positive FCFNegative FCF
Free Cash Flow
YoY Growth %
mitpf free cash flow history · mitpf free cash flow chart · mitpf free cash flow growth rate · mitpf free cash flow last 10 years

Annual free cash flow data

Fiscal YearFree Cash FlowYoY ChangeFCF Margin
FY2023Latest−$2.2M▲ +97.6%-5.4%
FY2022−$92.3M▲ +14.0%-137.8%
FY2021−$107.3M▼ 7.6%-473.5%
FY2020−$99.8M▼ 52.1%—
FY2019−$65.6M▼ 914.4%-68.0%
FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP
mitpf free cash flow 2023 · mitpf free cash flow 2022 · mitpf free cash flow 2021 · mitpf operating cash flow

FCF valuation metrics

Mithra Pharmaceuticals S.A. (MITPF) reported negative free cash flow of −$0.00B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)
N/A
Free Cash Flow ÷ Market Cap
per FMP freeCashFlowYieldTTM definition
FCF per Share (TTM)
N/A
TTM FCF ÷ Shares Outstanding
Price / FCF
N/A
Share Price ÷ FCF per Share
EV / FCF (TTM)
N/A
Enterprise Value basis
!

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2023 · 2023-12-31
mitpf price to free cash flow · mitpf free cash flow yield · mitpf free cash flow per share · mitpf price to cash flow ratio

Cash flow statement summary

For FY2023, Mithra Pharmaceuticals S.A. generated −$2.2M in operating cash flow and spent 0M in capital expenditures, yielding −$2.2M in free cash flow.

Operating Activities
−$2.2M
Cash from core business operations
2023-12-31
Investing Activities
+$3.5M
CapEx, acquisitions & investments
2023-12-31
Financing Activities
−$20.5M
Buybacks, dividends & debt
2023-12-31
FCF FormulaOperating CF (−$2.2M) − |CapEx| (0M) = FCF (−$2.2M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →
mitpf cash flow statement · mitpf cash flow statement 2023 · mitpf operating cash flow · mitpf cash flow from operations

Free cash flow vs peers (Healthcare)

#CompanyFree Cash FlowYoY
#1
Mithra Pharmaceuticals S.A.
Mithra Pharmaceuticals S.A.YOU
MITPF
−$2.2M+97.6%
#2
Johnson & Johnson
Johnson & Johnson
JNJ
$19.70B-0.7%#3
AbbVie Inc.
AbbVie Inc.
ABBV
$17.82B-0.1%#4
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$16.07B-22.4%#5
Eli Lilly and Company
Eli Lilly and Company
LLY
$8.97B+2065.6%
Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Mithra Pharmaceuticals S.A. (MITPF) reported free cash flow of −$2.2M for FY2023 (fiscal year ending 2023-12-31), up 97.6% year-over-year. The FCF margin was -5.4%.

Based on available data, Mithra Pharmaceuticals S.A. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $512,000 in FY2012.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.
RevenueFinancial statementsNet incomeEarningsForecastPrice historyMarket capCash on handP/E ratio

Frequently asked questions

MITPF free cash flow · 8 questions

Mithra Pharmaceuticals S.A. free cash flow was −$2.2M for FY2023, up 97.6% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$99.8M.

MITPF free cash flowMITPF FCFMITPF FCF 2023MITPF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Mithra Pharmaceuticals S.A. · Mithra Pharmaceuticals S.A. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026